Biocon inaugurates first manufacturing facility in US

Biocon Ltd has inaugurated its first US manufacturing facility in Cranbury, New Jersey, operated by its subsidiary, Biocon Generics Inc. Following the acquisition of the Oral Solid Dosage facility from Eywa Pharma Inc in 2023, Biocon invested over USD 30 million to establish the plant.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r8AKiHu
via IFTTT

Read More

Dr Reddy's inks pact with Johnson & Johnson to acquire vertigo treatment brand

Dr. Reddy's Laboratories has finalized its acquisition of the Stugeron brand from Johnson & Johnson, encompassing EMEA regions, India, and Vietnam. This strategic move allows Dr. Reddy's to broaden its presence in the anti-vertigo market and reinforce its Central Nervous System portfolio. The company aims to extend Stugeron's reach across 18 key markets, aligning with its goal of reaching 1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ipQhes9
via IFTTT

Read More

Delhi HC stops drug body from taking action against IndiaMart

The Delhi High Court has temporarily blocked the CDSCO from pursuing criminal action against IndiaMart for allegedly listing unapproved medicines. This decision follows complaints regarding the online marketplace listing drugs like Crysvita, Oxbryta, and Jynneos, which are not approved for sale in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nzouJ3S
via IFTTT

Read More

Indian hospitals to raise IT innovation spend by 25% in 3 years: Report

Indian hospitals are poised to significantly increase their IT innovation spending, with a large portion of healthcare providers already dedicating a substantial part of their IT budgets to digital advancements. The focus will be on enhancing patient experience, improving clinical outcomes through technology, and enabling data-driven decision-making.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2npRztj
via IFTTT

Read More

WHO adds popular weight-loss drugs to essential medicines list

The World Health Organization has included Semaglutide and Tirzepatide, popular weight-loss drugs, in its Model List of Essential Medicines. This decision could significantly lower the prices of these medications in countries like India, where obesity rates have surged. The WHO aims to improve access and health outcomes by prioritizing those in need and encouraging generic competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/B7hnD36
via IFTTT

Read More

Medicines may soon come with braille labels, audio QR codes

India's drug regulatory authority is exploring the addition of braille cards and voice-assisted QR codes on medicine strips to improve accessibility for visually impaired individuals. This initiative follows representations highlighting the difficulties faced by blind individuals in identifying medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u7VMezX
via IFTTT

Read More

Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: Report

A Systematix Research report indicates the Indian pharmaceutical industry is navigating uncertainty due to US tariffs, necessitating price increases, site transfers, and IP transfers. While raw material prices stabilize and companies explore new growth avenues, first quarter earnings were weak, with margin pressures in the US market. Firms cautiously evaluate inorganic growth and focus on OTC platforms amid these challenges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ONbHWxd
via IFTTT

Read More

The missed window: Why half of India’s people with diabetes learn too late

Many Indians unknowingly live with diabetes, missing the crucial early detection window. This delay, often due to subtle symptoms and lifestyle factors, leads to severe complications like kidney damage and heart issues. Early screening, awareness of risk factors, and regular check-ups are vital to managing diabetes and preventing long-term health problems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c1nQTlv
via IFTTT

Read More

Health experts alarmed by GST cut on beedis, demand uniform taxation

Health experts have criticised the government’s move to cut GST on beedis from 28% to 18% while keeping other tobacco products at 40%. They warned cheaper beedis, widely used by poor communities, could worsen India’s tobacco burden. Doctors stressed beedis are as harmful as cigarettes, urging uniform high taxes to curb use, protect vulnerable groups, and reduce health costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oL06EuC
via IFTTT

Read More

AstraZeneca to invest Rs 176 cr to expand GITC in Chennai

AstraZeneca is investing Rs 176 crore to expand its Global Innovation & Technology Centre in Chennai, marking its third investment in India in two years. This expansion will enhance the center's capabilities in AI, data analytics, and machine learning, supporting the development of next-generation medicines and digital healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aDime8O
via IFTTT

Read More

USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit

Aurobindo Pharma faces scrutiny. The US FDA inspected its Bachupally, Telangana plant. The inspection occurred between August 25 and September 5. Following the inspection, the US FDA issued a Form 483. The form contained eight observations. Aurobindo Pharma stated the observations are procedural. The company plans to respond to the US FDA within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kXtOaJq
via IFTTT

Read More

Glenmark initiates multi-nation Phase 3 clinical trial for lung cancer drug

Glenmark Pharmaceuticals has commenced a Phase 3 clinical trial across multiple countries, including India, Russia, Brazil, and Mexico, for Envafolimab, a novel drug targeting third-stage non-small cell lung cancer (NSCLC). The trial aims to evaluate the drug's efficacy, safety, and other key parameters in NSCLC patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WKbNkqL
via IFTTT

Read More

Type 2 diabetes triggering heart attacks in the 30s: Why India’s youth are at risk?

Type 2 diabetes is increasingly affecting young Indians, accelerating heart disease risks due to factors like genetics, visceral fat, and unhealthy lifestyles. Modern diets high in fats and sugars, coupled with sedentary habits and mental stress, significantly contribute to early heart attacks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xi5b1HV
via IFTTT

Read More

Pharma companies cheer lower drug prices, API tax gap stirs worry

Goods and Services Tax reforms are expected to reduce medicine prices in India. Experts say this will benefit patients and businesses. However, concerns exist regarding the higher tax rate on Active Pharmaceutical Ingredients. This could increase working capital pressure, especially for smaller companies. Provisional refunds may help mitigate these challenges. The government has reduced GST on several expensive medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rJcQTk6
via IFTTT

Read More

GST cut on drugs, medical devices to provide relief to patients: Industry players

The government is reducing GST on medicines and medical devices. Lifesaving drugs are exempt. This action will help patients and families. It will also make healthcare more affordable. Sudarshan Jain and Anil Matai welcome the changes. Ameera Shah and Shobana Kamineni also support the move. Himanshu Baid says it will improve access to medical technologies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9WnEXcQ
via IFTTT

Read More

Crucial drugs to be more affordable after GST cut

The government has significantly reduced GST rates on 41 highly priced medicines, including those for cancer, rare diseases, and heart conditions, aiming to make healthcare more affordable. Key drugs like Risdiplam and daratumumab will now have zero GST, benefiting patients with spinal muscular atrophy and multiple myeloma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3D0ben
via IFTTT

Read More

Centre set to amend rules to simplify drug testing process

The Indian government is amending drug regulations to expedite the approval process for clinical trials and bioavailability/bioequivalence studies. These changes aim to reduce the statutory processing time for test license applications from 90 to 45 days. By simplifying procedures and reducing the number of license applications, the government anticipates faster drug development and approval, benefiting stakeholders and optimizing resource allocation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kijh5TH
via IFTTT

Read More

Alkem's Enzene powers into US with $70 m investment

Enzene Biosciences, an Alkem Labs subsidiary, has inaugurated a new US manufacturing plant. The facility is located in New Jersey. This venture represents a $70 million investment. It aligns with calls to boost local pharma manufacturing. Enzene's technology offers cost-effective drug production. The company currently employs 50 people. Enzene plans to increase its workforce to 200.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FW6hpHG
via IFTTT

Read More

Singapore-based firm proposes to acquire 25% in Welcure Drugs & Pharma

Welcure Drugs & Pharmaceuticals receives an offer from Telexcell Trade. Telexcell Trade, based in Singapore, plans to acquire a 25 per cent stake. The indicative price is Rs 20 per share. This investment aims to expand Welcure's global presence. The all-cash investment is estimated at Rs 52 crore. Welcure intends to invest in an agro-pharma research lab.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oVTei6H
via IFTTT

Read More

Lupin gets USFDA nod for generic risperidone extended-release injectable suspension

Lupin Ltd. secured USFDA approval for its generic risperidone extended-release injectable suspension, a treatment for schizophrenia and bipolar disorder. This marks Lupin's first product utilizing Nanomi BV's technology, benefiting from 180-day competitive generic therapies exclusivity. The drug, with estimated annual sales of USD 190 million, expands access to complex injectables for patients globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5cr3uk
via IFTTT

Read More

Caplin Point arm gets USFDA nod for milrinone lactate in 5 pc dextrose injection

Caplin Point Laboratories' arm, Caplin Steriles, secured USFDA approval for its generic milrinone lactate in 5% dextrose injection. Indicated for acute decompensated heart failure, the injection is a generic version of Sanofi Aventis' PRIMACOR. The US market for this injection reached approximately USD 11 million in sales for the year ending July 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sRMWo3w
via IFTTT

Read More

Medical device manufacturers allowed to give free samples

Medical device companies in New Delhi can now give doctors free samples. There are rules for this. The sample's price must match what stockists pay. If the company bought the sample, that price counts. Company CEOs must ensure code compliance. Marketing costs must be disclosed yearly. This promotes ethical marketing and benefits both manufacturers and patients in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6CKwkI5
via IFTTT

Read More

India eyes Russia, Brazil, Netherlands for pharma export growth as US tariffs concerns linger

India is strategically planning to boost its pharmaceutical exports to Russia, the Netherlands, and Brazil, aiming to reduce reliance on the U.S. market due to tariff concerns. While the U.S. remains a crucial market, India seeks to diversify its export chain and increase market share in these growing regions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i1YXg7P
via IFTTT

Read More

Glenmark launches generic cancer treatment drug in US

Glenmark Pharmaceuticals on Tuesday launched Eribulin Mesylate Injection, a generic cancer treatment, in the US through its subsidiary Glenmark Pharmaceuticals Inc., USA. The product, equivalent to Eisai’s Halaven Injection, will begin distribution this month.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GA9Vtaz
via IFTTT

Read More

Zydus launches VaxiFluTM trivalent influenza vaccine for flu protection in India

Zydus Lifesciences has introduced VaxiFlu, a trivalent influenza vaccine, in India. This vaccine aligns with WHO guidelines. It is for individuals aged six months and above. The vaccine contains updated strains for optimal protection. Flu remains a global health concern. It causes millions of severe illnesses and respiratory deaths annually. VaxiFlu aims to reduce vaccine-preventable diseases, especially in high-risk groups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HVIgytb
via IFTTT

Read More

Fortis Healthcare arm inks 15-year lease with RR Lifesciences to expand NCR reach

Fortis Healthcare's subsidiary, International Hospital Limited, has secured a 15-year lease. This agreement with RR Lifesciences Limited allows Fortis to operate and expand its facility in Greater Noida. Fortis will now have complete control over the 200-bed hospital, known as Fortis Hospital Greater Noida. The hospital aims to increase its capacity to approximately 250 beds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AhIEa3Z
via IFTTT

Read More

The #WeightofDiabetes iceberg: Why the real burden lies beneath the surface

India faces a significant diabetes crisis, with millions undiagnosed, increasing the risk of heart disease. Early detection through screening and lifestyle changes like diet and exercise are crucial. Community programs and modern treatments offer hope for managing diabetes and improving long-term health outcomes, reducing the economic and health burden.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8tuywW5
via IFTTT

Read More

Govt launches advanced biomanufacturing hubs to boost bioeconomy, innovation

India has launched a network of advanced biomanufacturing hubs to boost its bioeconomy and drive innovation across sectors like health, agriculture and energy. This initiative, under the BioE3 Policy, provides state-of-the-art infrastructure and expertise to startups and researchers. India aims to achieve a USD 300 billion bioeconomy by 2030, positioning itself as a global leader in biotechnology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dE9MpFX
via IFTTT

Read More

Novo Nordisk ties up with Apollo Clinics for obesity management initiative

Novo Nordisk partners with Apollo Clinics to tackle obesity in India. The collaboration introduces a comprehensive obesity management programme across Indian cities. This initiative aims to provide structured care through multiple levels. The partnership focuses on equipping healthcare professionals with tools and support. The goal is to deliver personalized, evidence-based interventions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ok3qBwd
via IFTTT

Read More

Pharmaceutical industry seeks relief from rate inversion

The pharmaceutical industry in India anticipates potential relief from Goods and Services Tax inversion. Discussions between companies and the government suggest a favourable resolution within upcoming GST reforms. The current tax structure creates working capital issues, especially for MSMEs. Delayed refunds force MSMEs to take loans. Exporters face strain paying upfront taxes on APIs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tmQ3Cg8
via IFTTT

Read More

Indian hospitals battle central line infections linked to mismanagement of tubes used for administering medicines and fluids

A seven-year Indian study reveals alarmingly high rates of bloodstream infections from central lines, especially in newborns, with a 40% mortality rate within two weeks. The infection rate is significantly higher than in the US, exacerbated by antibiotic resistance and overwhelmed ICUs during COVID-19. Experts emphasize the need for improved monitoring, infection control, and staffing to reduce these preventable infections.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7DMYBQw
via IFTTT

Read More

Repurposed anti-cholesterol drug statin can stymie cancer, help support treatment, say researchers

Statins, drugs for high cholesterol, show promise in slowing colorectal cancer growth. Researchers at Shiv Nadar University and IISER Pune found statins target key pathways in cancer cells. The study suggests statins could be repurposed for cancer treatment. More trials are needed to confirm these findings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L8WiavN
via IFTTT

Read More

Scientists find why ultra-processed diets make you gain fat even without extra calories: Study

A recent study reveals that consuming ultra-processed foods leads to greater weight gain compared to minimally processed diets, even with the same calorie intake. The research, involving healthy young men, also found that ultra-processed diets disrupt hormone levels and introduce pollutants linked to decreased sperm quality. These findings underscore the detrimental impact of processed foods on metabolic and reproductive health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r3YSEcZ
via IFTTT

Read More

Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026

Zydus Therapeutics reveals encouraging outcomes from Saroglitazar's clinical trial. The drug targets Primary Biliary Cholangitis. The EPICS-III trial demonstrates improved liver function in patients. These patients did not respond to standard treatment. Zydus plans to seek US regulatory approval in early 2026. Saroglitazar is a novel treatment option. It addresses bile acid toxicity and liver inflammation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vjFK0CD
via IFTTT

Read More

Murae Organisor plans to boost agro-sector presence under Rs 80-cr investment strategy

Murae Organisor Ltd is set to bolster its agro-sector presence with an Rs 80 crore investment in R&D and infrastructure. The plan includes establishing an Agro R&D Laboratory, developing processing and packaging infrastructure, and implementing digital traceability systems. This strategic move follows the company's proposed qualified institutional placement (QIP) of up to Rs 80 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fk4UOZS
via IFTTT

Read More

IHH Healthcare to add 2,000 beds in India by 2028

IHH Healthcare plans to expand its presence in India by adding approximately 2,000 new beds by 2028. This expansion will be facilitated through its subsidiaries, Fortis Healthcare and Gleneagles Healthcare, which currently operate 35 hospitals with over 5,000 beds across 11 states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QxuECrd
via IFTTT

Read More

FDA approves updated COVID-19 shots but limits access for some kids and adults

U.S. regulators have approved updated COVID-19 shots from Pfizer, Moderna, and Novavax, but access is now limited for younger adults and children to those with high-risk conditions. Pfizer's vaccine is no longer available for children under 5, while Novavax's shot is restricted to those 12 and older. These changes reflect a shift in U.S.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4z301L6
via IFTTT

Read More

Catching heart disease in its quietest moments in Type 2 diabetes

Early detection of heart disease in Type 2 diabetes is crucial, as it often develops silently. Advanced tests like high-sensitivity blood work, imaging, and genetic screening can identify hidden risks before symptoms appear. Proactive measures, including lifestyle changes and personalized medication, can significantly reduce cardiovascular complications and improve outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6ByGFHL
via IFTTT

Read More

Drug, medtech companies fear GST changes may squeeze funds

Pharma and medtech sectors are concerned about upcoming Goods and Services Tax changes. They anticipate higher operating costs and working capital issues. Rajiv Nath suggests a balanced GST approach for equipment and consumables. Federation of Pharma Entrepreneurs urges lower GST on APIs to avoid inverted duty structure. MSMEs fear blocked funds and slowed growth due to tax imbalances.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZTCn0xy
via IFTTT

Read More

Dr Reddy's expects new GST framework to address critical issues impacting pharma sector

Dr Reddy's Laboratories anticipates that the new Goods and Services Tax structure will address existing challenges. It will also create a rationalised tax framework for the pharmaceutical sector. The Association of Indian Medical Device Industry seeks to retain 12 percent GST for most consumables. It also wants 5 percent rate on costly equipment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LN2v7zg
via IFTTT

Read More

Dr Reddy's launches novel drug for chronic constipation management

Dr Reddy's Laboratories has introduced Colozo, a generic drug for chronic constipation in India. This medication, Linaclotide, is approved by the USFDA. It addresses chronic idiopathic constipation and irritable bowel syndrome. This launch strengthens Dr Reddy's gastrointestinal segment. It follows the introduction of BixiBat in India last year. The company aims to improve patient care and serve 1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xGuUVvT
via IFTTT

Read More

Sampre Nutrition inks 3-year manufacturing pact with Rama Exports for nutraceuticals

Sampre Nutrition has partnered with Rama Exports in a manufacturing agreement to produce nutraceuticals and food products. Sampre Nutrition will handle manufacturing, supply, quality assurance, and packaging, while Rama Exports will purchase the finished goods over a three-year contract. This agreement is projected to generate Rs 15 crore in business, boosting Sampre Nutrition's revenue and strengthening its operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HPuawKj
via IFTTT

Read More

GSK enters into oncology segment; launches therapies for gynaecological cancers

GlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological cancers. These therapies address unmet needs in endometrial and ovarian cancer treatment, with incidence projected to rise significantly by 2045. Jemperli offers targeted immunotherapy for advanced endometrial cancer, while Zejula provides first-line maintenance therapy for advanced ovarian cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UfkMqiF
via IFTTT

Read More

From Clinic to Crisis: How Poor Follow-Up Fuels the Type 2 Diabetes Epidemic

Many individuals with diabetes in India are unaware of their condition, leading to missed opportunities for early treatment and increased health risks. Regular follow-up appointments are crucial for monitoring progress, identifying early warning signs, and adjusting treatment plans to prevent complications. Skipping these check-ups can result in silent damage to vital organs and faster progression of the disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/P2zhxni
via IFTTT

Read More

India's healthcare chains set their hearts on foreign patients

Indian healthcare providers are aggressively pursuing a larger share of the medical tourism market, fueled by a significant increase in foreign patients seeking treatment. Tourist arrivals for medical reasons have surged, with hospitals now attracting patients from Europe and the UK, in addition to traditional markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aplvDgO
via IFTTT

Read More

Global PE firms tighten grip on India’s $80-billion hospital sector

India's private hospital sector has seen a significant shift towards ownership by global private equity firms in the last five years, especially after the Covid-19 pandemic. This trend is reshaping the healthcare market, attracting investments from entities like Temasek, TPG, and KKR.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HKgSMQC
via IFTTT

Read More

IMA warns of misuse, mis-prescription of new weight-loss drugs, such as Wegovy and Mounjaro

The Indian Medical Association is raising concerns about the misuse of weight-loss drugs like Wegovy and Mounjaro, urging stricter prescription controls. They plan to petition the health ministry and drug regulator, advocating for prescriptions to be limited to certified endocrinologists or diabetologists. Rampant prescriptions by cosmetologists and other non-specialists are fueling concerns about potential side effects and improper usage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UcrkMaY
via IFTTT

Read More

Novo Nordisk warns patients after theft of weight-loss, diabetes drugs

Novo Nordisk urges customers to purchase medications solely from authorized pharmacies with valid prescriptions after a theft of products, including semaglutide and insulin treatments, during transportation. The company is cooperating with authorities and reinforcing supply chain safeguards. CDSCO has issued an alert, advising caution and vigilance in procuring Novo Nordisk products from trusted sources due to potential compromised quality.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vU71Iaq
via IFTTT

Read More

CDSCO issues alert on Novo drugs after reported theft

The CDSCO has alerted healthcare professionals and consumers about stolen Novo Nordisk products, including semaglutide and insulin injectables. These products, requiring specific temperature control (2-8°C), may be compromised if improperly stored. The regulator has instructed state drug control offices to monitor the market and take action under the Drugs and Cosmetics Act, 1940, while police investigate the theft during transit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GRFfUEp
via IFTTT

Read More

Substantial cancer drugs beyond ambit of current price control mechanisms: Parliamentary panel

A parliamentary panel has urged for broader price controls on cancer drugs, noting that many remain unaffordable. The committee recommends regular market assessments, quality monitoring of generic medicines, and enhanced domestic research. Streamlining regulatory pathways and fostering public-private collaboration are crucial for improving access to novel therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vsfilqK
via IFTTT

Read More

Stricter shelf life rule a bitter pill to swallow for pharma companies

A new regulation by the CDSCO mandates that exported drugs must have at least 60% shelf life remaining, causing significant losses to the Indian pharmaceutical industry. Manufacturers are now forced to destroy stocks to comply with this rule. The industry is urging for a revision, citing unnecessary losses and questioning the need when importing countries permit shorter shelf lives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGhcLye
via IFTTT

Read More

Drugmaker Novo Nordisk freezes hiring for non-critical jobs

Novo Nordisk, the maker of Wegovy, has initiated a global hiring freeze for non-critical roles amid increasing competition and pressure from Eli Lilly. This decision follows a profit warning that led to a significant drop in market value and the appointment of a new CEO, Mike Doustdar, who is considering cost-saving measures, including potential layoffs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RsJVMF5
via IFTTT

Read More

Natco Pharma launches generic drug with 180-day exclusivity in US

Natco Pharma has launched Bosentan tablets, a generic version of Tracleer, in the US for treating pulmonary arterial hypertension in young patients. This launch comes with 180-day exclusivity. Lupin Ltd. is Natco's marketing partner for this product. The drug had estimated sales of USD 10 million in the US for the 12 months ended June this year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J5HvGMB
via IFTTT

Read More

When the heart and sugar collide: The overlooked risk in Type 2 diabetes

Type 2 diabetes significantly elevates the risk of heart disease due to high blood sugar damaging arteries, leading to plaque buildup and reduced blood flow. Recognizing subtle symptoms like chest pain or shortness of breath is crucial for early intervention. Simple lifestyle adjustments, including a balanced diet, regular exercise, and stress management, can significantly protect heart health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tNAOYfd
via IFTTT

Read More

Aurobindo Pharma closing in on $5.5b Zentiva buyout

Largest Indian pharma M&A in final lap; PE firm GTCR only other contender. A portfolio company of Advent International, Zentiva will significantly boost Aurobindo’s European footprint.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sa0FGJC
via IFTTT

Read More

Indian drugmakers seek exemption for generics from US supplies probe

Indian pharmaceutical industry representatives met with Union Commerce Minister Piyush Goyal. They requested the US government to exclude generic drugs from its investigation into pharmaceutical imports. The probe, under Section 232, raises concerns about supply chain disruptions. This discussion occurs amidst India-US trade negotiations and potential US tariffs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J3tBKf9
via IFTTT

Read More

Glenmark, Alembic Pharma, Sun Pharma recall products in US: USFDA

Glenmark, Alembic Pharmaceuticals, and Sun Pharma are recalling various products in the US due to manufacturing issues, according to the USFDA. Glenmark is recalling Carvedilol tablets due to nitrosamine impurity and Theophylline tablets for failed dissolution. Alembic is recalling Doxepin capsules for a similar impurity issue, while Sun Pharma recalls Spironolactone tablets due to aluminum contamination.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/82y5NSr
via IFTTT

Read More

Alembic gets USFDA nod for generic drug for skin condition

Alembic Pharmaceuticals has secured USFDA approval for its generic Tretinoin Cream USP (0.025%), a treatment for acne vulgaris. This ANDA is therapeutically equivalent to Bausch Health US, LLC's Retin-A Cream. The market size for Tretinoin cream USP (0.025%) is estimated at USD 94 million for the twelve months ending June 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rQjfEAB
via IFTTT

Read More

Aurobindo Pharma expects China plant to break even at EBITDA level this year

Aurobindo Pharma anticipates its China facility will achieve break-even by Q3 FY26. Production is ramping up after commencing operations in November 2024. The company invested USD 145 million in the facility. Aurobindo Pharma also invested in US facilities and plans to file for products in the US and Europe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hs24qbj
via IFTTT

Read More

Food Chained: How weight-loss drugs are changing India’s eating habits and forcing restaurants to take note

New diabetes and obesity drugs, like Mounjaro and Ozempic, are changing people's relationships with food. While these drugs help control diabetes and promote weight loss by altering taste and reducing hunger, some users experience a loss of enjoyment in eating and even develop food anxieties.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qipXT2j
via IFTTT

Read More

Max Healthcare to nearly double capacity to 9,500 beds by 2028 after strong quarterly growth

Max Healthcare Institute aims to nearly double its bed capacity to 9,500 by 2028 through brownfield and greenfield expansions, following a 35% increase to 5,000 beds last year. The company reported a 27% jump in first-quarter revenue to Rs 2,574 crore and a 17% rise in net profit to Rs 345 crore, driven by higher occupancy and international patient revenue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tES5J9n
via IFTTT

Read More

Cohance Lifesciences announces $10 million investment in US-based arm

Cohance Lifesciences is investing USD 10 million to expand bioconjugation capabilities at its US subsidiary, NJ Bio, enhancing its ADC solutions. This investment aims to support innovators from early development through late-phase clinical supply. Additionally, Cohance is investing Rs 23 crore in a new oligonucleotide building block manufacturing facility in Hyderabad, part of a broader capacity expansion program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G6moSWY
via IFTTT

Read More

From burden to breakthrough: Reimagining the #WeightofDiabetes through meaningful conversations with your doctor

Effectively managing type 2 diabetes involves more than just medication; it requires open communication with healthcare providers to address weight, heart health, and emotional well-being. Proactive conversations can clarify confusion, uncover barriers, and empower individuals to take charge of their health, preventing crises and promoting resilience through personalized care and support.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n6QNrjO
via IFTTT

Read More

Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million

Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tpuhbM4
via IFTTT

Read More

Lupin ties up with Sandoz to commercialise biosimilar product

Lupin has partnered with Sandoz Group AG to commercialize its biosimilar ranibizumab across multiple regions, with Sandoz handling commercialization in the EU (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will manufacture the product and manage regulatory submissions. Sandoz also gains exclusive rights for commercialization in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9LHTCSq
via IFTTT

Read More

Chemists seek ban on quick commerce sale of prescription drugs

The All India Organisation of Chemists and Druggists (AIOCD) has appealed to Amit Shah. They want immediate action against e-pharmacies and quick commerce platforms. These platforms are selling prescription medicines online. AIOCD says this poses a public health risk. They are concerned about drug abuse, especially among young people. AIOCD also highlights the issue of ghost prescriptions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XILAdwq
via IFTTT

Read More

Asia Healthcare Holdings to invest Rs 400 crore in Asian Institute of Nephrology and Urology to double hospital network

Asia Healthcare Holdings will invest Rs 400 crore in Asian Institute of Nephrology and Urology. The investment will occur over the next 4-5 years. AINU plans to expand by opening 13 hospitals in Tier 2 cities. This expansion includes cities like Patna and Bhubaneshwar. The total investment will reach Rs 1,000 crore by FY30.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FypJzrY
via IFTTT

Read More

Pfizer launches next-gen vaccine for pneumococcal disease

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, offering protection against 20 serotypes responsible for a majority of pneumococcal diseases. This single-dose vaccine provides timely and proactive protection for all adults, including those with chronic conditions, potentially eliminating the need for a second dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T8l6hCc
via IFTTT

Read More

Welcure Drugs & Pharma board to consider share split, bonus issue this month

Welcure Drugs & Pharmaceuticals is set to consider a stock split of 1:10 and a bonus issue of 1:1 in its upcoming board meeting on August 22. This decision follows strong financial results in Q1 FY26, with revenue from operations reaching Rs 299.91 crore and net profit surging to Rs 23.29 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MIrfW2R
via IFTTT

Read More

Zydus Lifesciences gets USFDA approval for angina, high blood pressure drug

Zydus Lifesciences has secured USFDA approval to market Diltiazem Hydrochloride tablets, used for treating angina and high blood pressure, in strengths of 30 mg, 60 mg, 90 mg, and 120 mg. The medication, a calcium-channel blocker, relaxes blood vessels, easing the heart's workload and improving blood flow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4CdspvA
via IFTTT

Read More

Retinal disorders a public health crisis, need immediate prioritisation, say experts

Mission Vision, a public health initiative, has launched in India to combat the escalating crisis of vision loss due to Diabetic Retinopathy. The initiative aims to increase awareness, improve screening and treatment access, and integrate eye care into routine diabetes management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UecTf9s
via IFTTT

Read More

Managing diabetes in a country obsessed with quick fixes: A scientific perspective

Diabetes management faces challenges due to patients' preference for quick fixes over sustainable lifestyle changes. These shortcuts, like extra medication or unproven supplements, offer temporary relief but neglect long-term disease control. Shifting mindsets requires holistic approaches, personalized support, and collaborative healthcare to promote lasting healthy habits and prevent complications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wmz1MyF
via IFTTT

Read More

Govt gives BIS exemption to parts used in medical devices for now

The steel ministry has temporarily suspended its notification requiring Indian standards compliance for raw materials used in medical device manufacturing, offering relief to the industry. They will issue no-objection certificates for importing special stainless steel grades and allow foreign suppliers six months to obtain Bureau of Indian Standards registration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xAzXsHv
via IFTTT

Read More

Biocon sees GLP-1 weight-loss therapy as a future growth driver

Biocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 India launch. CEO Shreehas Tambe said both portfolios are complementary. Biocon aims to leverage its insulin experience for GLP-1 success, following US FDA approval for insulin aspart and India approval for liraglutide. External risks remain a key concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dw4pEIK
via IFTTT

Read More

Medical device firms sound the alarm over new steel standards

Earlier, foreign suppliers only needed BIS certification for finished steel products. Under the new rule, materials like hot rolled steel, ingots manufactured by other countries for Indian buyers will have to get BIS certification. The manufacturers have written to the ministry of steel seeking exemption for the import of stainless steel capillary without BIS certification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FurWfSZ
via IFTTT

Read More

Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months

The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro’s revenue could cross Rs 500 crore by March, experts estimate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xLPVHcg
via IFTTT

Read More

Novo Nordisk's Wegovy, Mounjaro sales in India double on month in July

Sales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, launched in June, saw sales more than double to 5,000 units, while Mounjaro sales also doubled to 157,000 units. Mounjaro's sales have soared 15 times since its March launch in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AhPSKaq
via IFTTT

Read More

Executive order by US administration excludes Pharma sector from immediate tariff imposition: Indian Pharmaceutical Alliance

The Indian pharmaceutical sector has been excluded from immediate US tariff hikes due to the importance of generic medicines for affordable healthcare in the United States. This follows President Trump's imposition of a 25% tariff on India over Russian oil purchases, raising the total tariff to 50%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bkQCuVn
via IFTTT

Read More

Indian pharma on alert as US mulls higher drug tariffs

Indian drug makers are assessing the potential consequences of additional tariffs imposed by the US in response to India's oil purchases from Russia. While previous tariffs spared pharmaceuticals, uncertainty prevails due to frequent policy changes. Companies are exploring mitigation strategies like price adjustments and technology transfer to the US, anticipating manageable impacts on medicine access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JTxi1wE
via IFTTT

Read More

More heart attacks in diabetes? Here’s what you should know

Type 2 diabetes elevates the risk of heart issues, but advancements offer hope. New treatments not only manage blood sugar but also promote weight loss, lower blood pressure, and improve cholesterol, reducing heart-related hospitalizations. Addressing obesity is crucial, and consulting a doctor about comprehensive diabetes and heart health management is recommended.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GwPz60k
via IFTTT

Read More

Indian generics wave next year set to sink obesity drug price

Leading Indian drugmakers are preparing to launch generic versions of semaglutide by March. Analysts predict a significant price drop, potentially up to 80%. This will make the drug more accessible to obese and diabetes patients. The domestic weight-loss drug market is expected to grow substantially. Semaglutide patent expiry will trigger price erosion and increased adoption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0384zN
via IFTTT

Read More

Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COO

Eris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims for a significant market share. Several Indian drugmakers are also preparing to launch generic versions. Eris has experience with diabetes drugs. The company hopes to leverage its existing portfolio. It includes orals, insulin, and GLP-1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0wQPGY2
via IFTTT

Read More

Pharma tariffs may go as high as 250%, says Trump

U.S. President Donald Trump said new tariffs on imported pharmaceuticals will start small but could rise to 250% within 18 months to boost domestic production. He also plans to announce fresh duties on foreign semiconductors, aiming to reduce U.S. reliance on overseas supply chains.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xS1FQAT
via IFTTT

Read More

Mind, muscle, and metabolism: The power of holistic diabetes management

Managing diabetes holistically involves more than just blood sugar control, encompassing lifestyle factors like diet, exercise, and mental well-being. Small changes, such as increasing fiber intake and regular walking, can significantly impact health. Understanding hormones like GLP-1 and insulin, along with addressing stress and sleep, are crucial for comprehensive diabetes care and improved overall well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/THnDtI9
via IFTTT

Read More

Corner Office Conversation with The New Leaders of Indian Pharma

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yagzUpd
via IFTTT

Read More

Manipal Hospitals seeks CCI nod to acquire Sahyadri Hospitals for about Rs 6,400 cr

Manipal Hospitals is planning to acquire Sahyadri Hospitals. The deal is estimated at around Rs 6,400 crore. Manipal has sought approval from the Competition Commission of India. This acquisition will significantly expand Manipal's presence in western India. It will also increase Manipal's total bed count to approximately 12,000. Sahyadri Hospitals currently operates 11 hospitals in Maharashtra.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Iv06Knp
via IFTTT

Read More

70% enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre

India achieves a milestone in dengue prevention. The DengiAll vaccine trial sees 70% participant enrollment. ICMR leads the multi-center study across 20 Indian sites. The budget is approximately Rs 1.3 to 1.5 crore per site. Dengue cases are rising, with over 5 lakh confirmed in 2024. The government monitors outbreaks and provides support to states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZYMrA1o
via IFTTT

Read More

Apollo entities seek CCI nod for recast plan

Apollo Group is seeking CCI's approval for a restructuring plan to list its omnichannel pharmacy and digital health businesses within 18-21 months. This involves merging Apollo's digital platforms and Keimed into Apollo Healthtech, creating a major player with ₹16,300 crore in FY25 revenues. Subsequently, Apollo Healthtech will acquire a 74.5% stake in Apollo Medicals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZWrCon5
via IFTTT

Read More

Sun Pharmaceutical says it won't expand US manufacturing base amid tariff concerns

Sun Pharmaceutical, India's largest drug maker, is not planning to expand its manufacturing base in the US, citing sufficient existing capacity. The company remains watchful of potential reciprocal tariffs, though pharmaceuticals are currently exempt pending a US investigation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W67FCgn
via IFTTT

Read More

Pharma industry to outdo India Inc in 2025 pay hike: Study

Pharma companies in India are projected to offer an average salary increment of 9.6% in 2025, slightly lower than the previous year but still surpassing the 8.8% average for corporate India. Emerging roles like regen medicine researcher and digital health programme officer are expected to receive even higher increments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ucdsChJ
via IFTTT

Read More

Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underway

Driven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages. While giants like Novartis and GSK are cautious, Eli Lilly and Novo Nordisk lead the race. Research expands beyond GLP-1 targets, exploring oral options and addressing conditions like MASH and CVD.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j0HGQFk
via IFTTT

Read More

Medtech firms flag inflated MRPs on imported devices

Indian medical device manufacturers have raised concerns that private hospitals and retailers are favoring imported devices with inflated prices or missing MRPs to gain higher margins. This practice disadvantages domestic manufacturers, who offer similar products at lower costs. The industry has urged the government to investigate unfair trade practices and duty evasion related to excessive MRPs on imported devices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mci8hzB
via IFTTT

Read More

Pharma exporters expect Trump to act benevolently to them

Indian drug makers, heavily reliant on the US market, face potential challenges due to President Trump's proposed 25% reciprocal tariff on imports from India. While analysts anticipate a possible exemption or reduced tariff for the pharma sector, companies are preparing to pass on costs to customers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qjW5TRB
via IFTTT

Read More

650 private hospitals in Haryana to withdraw from Ayushman Bharat scheme over unpaid dues

Around 650 private hospitals in Haryana are threatening to halt Ayushman Bharat services from August 7 due to ₹500 crore in pending reimbursements. The Indian Medical Association (IMA) Haryana unit reports that hospitals have received only a fraction of their dues since March, creating a severe financial strain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1UVluDZ
via IFTTT

Read More

Jashvik Capital acquires Rs 400 crore stake in Marg ERP

Jashvik Capital has invested Rs. 400 crore for an undisclosed stake in Marg ERP, a company serving over 500,000 subscribers across multiple industries. Marg ERP's founders recently bought back a 49% stake from API Holdings. Jashvik Capital aims to leverage its expertise to help Marg ERP become a global healthcare SaaS leader.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GLhYBTW
via IFTTT

Read More

PE funds vie for a majority stake in medical devices maker Sensa Core

Several private equity firms, including KKR and TPG, are considering acquiring a majority stake in Sensa Core Medical Instrumentation. The deal could value the Indian medical device manufacturer at around $300 million. Sensa Core is a major producer of in-vitro diagnostic analysers. The medical device sector in India is attracting significant investor interest.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5WiSJbr
via IFTTT

Read More

Understanding the chain reaction of chronic diseases

Chronic diseases often occur together. Diabetes can damage blood vessels, affecting the heart and kidneys. Managing blood sugar and weight helps. The body produces hormones like insulin and GLP-1 to regulate blood sugar. Consult your doctor to understand the connections between your conditions. Holistic care improves overall health. Small steps can lead to big improvements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9QXZz63
via IFTTT

Read More

Monitor presence of potentially carcinogenic chemical in Ranitidine: DCGI to drug controllers

The DCGI has directed state and UT drug controllers to monitor levels of the potentially carcinogenic NDMA in Ranitidine, an antacid. This action follows concerns about NDMA impurity and recommendations from the Drugs Technical Advisory Board (DTAB). Manufacturers are urged to take risk-based measures, including shelf-life reduction, while ICMR considers a safety study.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nXCUWMv
via IFTTT

Read More

Maker of GLP1 pens scales up for generic debuts

As weight-loss drug sales surge with semaglutide's patent expiration, Gujarat's Shaily Engineering Plastics, an injector pen manufacturer, anticipates significant growth. Its stock has nearly doubled, and the company is doubling its production capacity to 80-85 million pens by fiscal year-end to meet rising domestic and export demands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yGJ7CbR
via IFTTT

Read More

Type 2 Diabetes diet plan: What to eat in a day

Struggling to manage type 2 diabetes through diet? Here’s a simple, balanced full-day eating guide with diabetic-friendly foods to stabilize blood sugar and boost energy levels naturally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u5d6SNx
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic Carbamazepine tablets

Alembic Pharmaceuticals has received final approval from the USFDA for its generic Carbamazepine extended-release tablets (100 mg, 200 mg, and 400 mg), used to treat seizures and nerve pain. The product is a generic version of Novartis’ Tegretol-XR. According to IQVIA, the U.S. market for these tablets is estimated at $71 million for the 12 months ending March 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YlgnM0c
via IFTTT

Read More

Cheaper cancer care therapy earns big bucks for pharma company

ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7auwHQG
via IFTTT

Read More

Does green coffee really help you lose weight? Here's the truth

Green coffee has become popular as a natural weight loss supplement, but how effective is it really? Here's a detailed look.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cmbn25G
via IFTTT

Read More

AIOCD demands strict action against illegal e-pharmacies; raises alarm over inaction by SLAs

The All-India Organisation of Chemists and Druggists raises concerns. It highlights the illegal operation of online pharmacies. These pharmacies violate drug regulations. AIOCD urges the government to take immediate action. They want a crackdown on unlicensed e-pharmacies. The organization calls for the withdrawal of certain regulations. These regulations are being misused. AIOCD emphasizes the need to protect public health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8ywhK2O
via IFTTT

Read More

Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues

Three major Indian pharmaceutical companies are recalling drugs in the United States. Sun Pharma is recalling Lisdexamfetamine capsules due to failed dissolution specifications. Lupin is recalling Lisinopril and Hydrochlorothiazide tablets because of product mix-up with Atazanavir and Ritonavir tablets. Dr Reddy's Laboratories is recalling Omeprazole capsules due to the presence of foreign Divalproex Sodium tablets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DZBhVbc
via IFTTT

Read More

Non-alcoholic fatty liver disease: An acute menace and a silent killer

Fatty liver disease is a growing health crisis due to obesity and poor lifestyles. Many individuals are unaware until imaging reveals the issue. A recent screening showed 65% had fatty liver, with normal enzyme levels in many. Teenagers are also affected. Untreated, it can lead to severe liver damage. Early screening and lifestyle changes are crucial for prevention.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qAhPTUK
via IFTTT

Read More

Experts flag UK-India FTA over patent terms, access to drugs

Concerns are mounting in India over the UK-India Free Trade Agreement's potential impact on access to affordable medicines. Experts fear the deal may weaken compulsory licensing norms, a crucial safeguard allowing generic drug production during public health emergencies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p1y7eBh
via IFTTT

Read More

Over 200 cancer day care centres to be established across India: Government

The Union Health Ministry has approved the establishment of over 200 Day Care Cancer Centres (DCCCs) across India for the financial year 2025-26, including 14 in Andhra Pradesh. These centres, prioritized based on ICMR data and state proposals, will be set up in district hospitals or other government facilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/roF6Idu
via IFTTT

Read More

Cipla targets $1 bn US revenue in FY27

Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics like Advair and Symbicort. The company also plans to launch peptide assets and its first biosimilar in the US by Q2 FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQEjwDN
via IFTTT

Read More

ICMR study found Covid vaccination didn't raise risk of unexplained sudden deaths among young adults: J P Nadda

An ICMR study found no link between COVID-19 vaccination and unexplained sudden deaths among young Indian adults. Instead, factors like past COVID hospitalization, family history, binge drinking, drug use, and intense physical activity were identified as key risks. Another AIIMS study confirmed heart attacks remain the leading cause of sudden deaths, with no post-pandemic pattern shift observed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6N2r4ds
via IFTTT

Read More

Delhi govt directs all pharmaceutical shops to install CCTV cameras to regulate sale of drugs without prescriptions

Delhi government mandates CCTV installation in all pharmacies by July 2025. This aims to stop the sale of low-quality and dual-use medicines without prescriptions. The focus is on high-risk drugs often misused by minors. Regular inspections and special drives will continue. Recent checks on anti-cancer drugs showed compliance with quality standards. These measures promote accountability and ensure drug safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QZYoDGL
via IFTTT

Read More

Duty relief to boost pharma companies' access to UK drug stores

The India-UK Free Trade Agreement is set to significantly benefit India's pharma and medical device industries. Tariff reductions and streamlined regulations will drive growth. Indian companies will gain easier access to the UK market. This will boost exports, especially for generics and biosimilars. The agreement also promotes cross-border research and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tSfPBnd
via IFTTT

Read More

7,000 steps a day may be the new magic number for better health: Lancet Study

A recent study in The Lancet Public Health reveals that walking at least 7,000 steps daily significantly reduces the risk of cardiovascular disease, cancer, type-2 diabetes, dementia, depression, and falls. Even 4,000 steps show health benefits compared to minimal activity. Researchers suggest 7,000 steps is a more achievable goal than 10,000 for improved health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O7DsMKG
via IFTTT

Read More

Natco Pharma to buy over 35% in South Africa's Adcock Ingram

Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings. The acquisition, expected to finalize in four months, aligns with Natco's strategy to grow in emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CVoQfkZ
via IFTTT

Read More

Apollo, Siemens collaborate to advance innovation in liver healthcare

Apollo Hospitals and Siemens Healthineers are collaborating to innovate liver healthcare through research. The partnership focuses on quantitative ultrasound imaging and AI-driven solutions to improve liver disease management. Their joint effort aims to enhance early detection, risk stratification, and monitoring of treatment response, ultimately improving patient outcomes and quality of life.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q9NfDA7
via IFTTT

Read More

Natco Pharma offers to acquire nearly 36% stake in Adcock Ingram in Rs 2,100-cr deal

Natco Pharma has made a firm offer to acquire nearly 36% stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore. This acquisition will provide Natco Pharma with a strong entry into the Southern African market and expand its footprint in a growing emerging market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IHrlhRp
via IFTTT

Read More

Biocon Biologics launches product for autoimmune diseases in Australia

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating autoimmune diseases like rheumatoid arthritis. Marketed through Generic Health, Nepexto aims to broaden patient access in the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZeVsntL
via IFTTT

Read More

Civil society organisations urge govt to scrap animal testing in biosimilar development

Civil society organizations are urging the health ministry to eliminate animal studies in biosimilar development to lower production costs and expedite the process. They emphasize that removing these tests will enhance affordability and uphold ethical standards. The government is revising biosimilar regulations, potentially restricting animal use and prioritizing in-vitro studies, aligning with global standards to ensure safety and efficacy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PenTDGJ
via IFTTT

Read More

PLI scheme for bulk drugs led to import savings of Rs 1,362 cr: Govt

India's PLI scheme for bulk drugs is showing positive results. It has reduced pharma raw material imports by Rs 1,362 crore until March 2025. The scheme spurred domestic manufacturing and exports. Investment under the scheme has already surpassed initial commitments. The government has also initiated a PLI Scheme for Pharmaceuticals with a total budgetary outlay of Rs 15,000 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QJzVsyj
via IFTTT

Read More

Godavari Biorefineries secures Chinese patent for breakthrough anti-cancer molecule

Godavari Biorefineries received a patent from China for its new anti-cancer molecule. The China National Intellectual Property Administration granted the patent. Sathgen Therapeutics, Godavari's biotech division, developed the molecule. The molecule, HYDROXY-1,4-NAPHTHALENEDIONE, shows promise in fighting cancer. In vitro studies showed it inhibits cancer and cancer stem cells. It is effective against breast and prostate cancer cells.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fey3ca6
via IFTTT

Read More

Obesity lab: India becomes ground zero for weight-loss drug race

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are launching innovative anti-obesity medications, while Indian companies gear up to produce affordable generic versions. Government support and incentives further position India as a major exporter of these crucial medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FsK6H18
via IFTTT

Read More

ADIA signs a definitive agreement to invest $200 million in medical devices firm Meril

Abu Dhabi Investment Authority (ADIA) is set to invest $200 million for a 3% stake in medical device maker Meril, valuing the company at $6.6 billion. This investment, pending CCI approval, will support Meril's growth and research efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SehyA24
via IFTTT

Read More

Abu Dhabi Investment Authority to buy 3% stake in Micro Life Sciences for $200 mn

Abu Dhabi Investment Authority (ADIA) is set to acquire a 3% stake in the Indian medical device company, Micro Life Sciences Pvt Ltd (Meril), for USD 200 million. This investment values Meril at USD 6.6 billion, pending regulatory approval from the Competition Commission of India (CCI). Meril plans to use the funds to accelerate growth and strengthen clinical research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rFMbOcD
via IFTTT

Read More

Brookfield, EQT close in on Gland Pharma, but rising stock a pain

The Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XMPWGYU
via IFTTT

Read More

Zydus Life's plans for cancer biosimilar hit a legal hurdle

The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infringement case filed by Bristol Myers Squibb concerning its anticancer drug Opdyta (nivolumab).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q40EjHC
via IFTTT

Read More

Dr Reddy's gets seven observations from USFDA for Andhra plant

Dr Reddy's Laboratories faces scrutiny. The USFDA issued a Form 483 after inspecting their Srikakulam facility. The inspection, which occurred in July 2025, revealed seven observations. These observations relate to potential violations of the Food, Drug and Cosmetic Act. Dr Reddy's plans to address these concerns promptly. The company aims to resolve the issues within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5DHes8o
via IFTTT

Read More

Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway

India is developing a new malaria vaccine. The Indian Council of Medical Research is leading the effort. The vaccine is called AdFalciVax. It targets two stages of the malaria parasite. Preclinical data shows excellent efficacy. The vaccine could prevent infection and reduce transmission. ICMR plans to license the technology to manufacturers. This aims to make the vaccine widely available.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KJ75uly
via IFTTT

Read More

Mind your posture: Doctors cite long hours in front of screen for increasing lifestyle diseases

Young professionals are increasingly facing lifestyle ailments due to prolonged sitting and screen time, leading to a 30-40% rise in muscular, spinal, eye, heart, and mental health disorders. The pressure to stay relevant in an AI-driven workplace exacerbates these issues, causing conditions like Tech Neck and Digital Fatigue Syndrome.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NRZwo7U
via IFTTT

Read More

New dilemma looms for India’s private hospitals: More beds, but few can lie in them

India's private hospital sector faces a potential overcapacity in major cities due to significant upcoming bed additions, even as smaller towns lack sufficient beds. While demand for quality healthcare grows, driven by rising incomes and insurance coverage, analysts caution that this expansion could strain profitability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DpnW9w0
via IFTTT

Read More

Sprays, pills, creams...ooh, aah, ouch? India’s pain market is now a Rs 16,000 cr giant

India’s pain relief market has exploded post-pandemic, doubling to nearly ₹16,000 crore in just five years. From gels and sprays to pills like Dolo and Zerodol, pain meds are now a daily fix for everything from gym soreness to chronic stress. The shift is lifestyle-driven and increasingly normalised, but experts warn against unchecked self-medication. As the over-the-counter space booms, driven by awareness and ease of access, the line between relief and risk is getting worryingly thin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2tuEaO7
via IFTTT

Read More

Central drugs laboratories find 55 samples to be 'not of standard quality' in June

In June 2025, central drugs laboratories discovered 55 drug samples failing quality standards, while state labs found 130 similarly substandard. The CDSCO regularly posts lists of these and spurious drugs. Additionally, one drug sample each from Bihar and Delhi, and two from Telangana, were identified as spurious, prompting investigations and regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vnuZJlp
via IFTTT

Read More

Kenvue ties up with API to launch India's first Cough Clinics

Kenvue, makers of Benadryl, introduces 'Cough Clinics' in partnership with the Association of Physicians of India. This initiative aims to establish ten Centers of Excellence across India. These clinics will enhance healthcare professionals' knowledge of cough evaluation. The goal is to promote science-backed approaches to treatment. The clinics will offer specialized training and tools for physicians.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H1E9tSQ
via IFTTT

Read More

Torrent Pharma seeks CCI nod to acquire majority stake in JB Chemicals for Rs 19,500 crore

Torrent Pharmaceuticals is looking to acquire J B Chemicals and Pharmaceuticals. The deal is worth Rs 19,500 crore. The company has sought clearance from the Competition Commission of India. After the deal, Torrent will become India's second most valued pharma company. Torrent will acquire a 46.39 per cent stake from Tau Investment. It will also buy 2.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BFv9ajx
via IFTTT

Read More

Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVie Inc. This deal, concerning ISB 2001, is expected to significantly strengthen Glenmark's financial standing and liquidity, reversing a previous net debt.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ibjoY94
via IFTTT

Read More

CORONA Remedies acquires 7 brands from Bayer's pharma division in India

CORONA Remedies has bought seven brands from Bayer's pharmaceutical unit in India. The deal includes Noklot for heart patients. Women's health brands like Fostine and Ovidac are also part of the acquisition. This move allows CORONA Remedies to enter a new heart treatment area. It also strengthens their position in women's healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0AdBOax
via IFTTT

Read More

Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugs

Glenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio and strengthening its branded business. By 2030, the company aims for 70% of its revenue to come from branded products, focusing on dermatology, respiratory, and oncology. A recent deal with AbbVie for its cancer drug ISB 2001 highlights this strategic shift.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ym1bgjE
via IFTTT

Read More

Domestic med-tech companies flag security threat from Chinese devices

Indian medical tech leaders have voiced concerns to the government regarding the security risks associated with importing Chinese healthcare devices. They highlighted potential misuse for surveillance, cyberattacks, and data breaches, urging stricter scrutiny and measures to prevent rerouting via other countries. Manufacturers also seek streamlined regulations and policy support to boost domestic production and achieve self-reliance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yDKMJ4j
via IFTTT

Read More

Biocon Biologics gets USFDA nod for diabetes medication

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It is a rapid-acting insulin analog. The medication will be available in prefilled pens and vials. This approval expands Biocon's insulin portfolio. Kirsty has been available in Europe and Canada since 2022. The US market for Insulin Aspart is significant.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t5qvzBc
via IFTTT

Read More

200% or more? Trump hints at 'very high tariffs' on pharma cos by August 1, says deal with India most likely

US President Trump had earlier suggested pharmaceutical tariffs could reach 200% after a year, incentivizing domestic manufacturing. On Tuesday, he said that an agreement with India was among the most likely.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/68QMApb
via IFTTT

Read More

Manipal Hospitals borrows Rs 5,300 crore from global banks to fund Sahyadri acquisition

Manipal Hospitals is securing ₹5,300 crore from foreign banks. This funding supports its acquisition of Sahyadri Hospitals. Deutsche Bank, Barclays, MUFG, SMBC, and DBS Bank are providing the debt. The total deal is around ₹5,900 crore. Manipal will issue bonds maturing in two years. An IPO is planned for 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0s8CIQY
via IFTTT

Read More

HLL Lifecare reports annual condom production of 221.7 cr

HLL Lifecare, a Kerala-based PSU, produces 221.7 crore condoms annually, solidifying its position as a leading global manufacturer. With eight factories across India, HLL significantly contributes to the nation's family welfare programs. Established in 1966 to address population growth, HLL has expanded beyond contraceptives, producing diagnostic kits, pharmaceuticals, and Ayurvedic medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aypom2c
via IFTTT

Read More

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

The National Pharmaceutical Pricing Authority (NPPA) has revised the prices of 71 essential drug formulations, encompassing treatments for metastatic breast cancer, diabetes, peptic ulcers, and severe infections. This revision aims to ensure affordability and accessibility of these crucial medicines. Retailers are now mandated to display the updated price lists for transparency and consumer awareness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/V3DSHNF
via IFTTT

Read More

Marengo Hospitals lines up ₹150 cr for western foray

Marengo Asia Healthcare, supported by Samara Capital and others, is set to expand into Maharashtra and Rajasthan with a ₹150 crore investment. The multi-specialty hospital platform aims to double its bed capacity from 1,500 to 3,000 by next year through strategic acquisitions and expansion of existing facilities, solidifying its position as a top healthcare leader in North and West India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jy5v3Ix
via IFTTT

Read More

Temasek building on India strategy with special focus on healthcare

Singapore's Temasek is significantly expanding its healthcare investments in India, prioritizing scalable and specialized platforms. Their recent backing of Manipal Hospitals' acquisition of Sahyadri Group demonstrates this strategy, creating a stronger presence in western India. Temasek aims to enhance accessibility and quality in underserved markets, focusing on profitable growth and strategic acquisitions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ze9VfyB
via IFTTT

Read More

Sun Pharma settles litigation with Incyte Corp

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, leading to the dismissal of pending litigation in the US. Incyte has granted Sun a non-exclusive license for oral deuruxolitinib for specific non-oncology indications, including alopecia areata, in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qHV6xcw
via IFTTT

Read More

Aayush Wellness expands nutraceutical product portfolio

Aayush Wellness introduced a new capsule for cognitive function. The company expands its nutraceutical line to address memory and focus issues. They aim to tap into the growing Indian nutraceutical market. Naveena Kumar highlights brain health's importance. Aayush Wellness recently entered tele-consultation and diagnostic testing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gzFLkZp
via IFTTT

Read More

Phase-3 clinical trial enrolment for India's first dengue vaccine to be completed by October: ICMR

India's DengiAll vaccine trial is nearing completion. ICMR scientists anticipate enrolling 10,500 participants by October across 20 Indian centers. The phase III trial assesses the Panacea Biotec's one-shot dengue vaccine. Initial trials showed no safety concerns. Participants will be monitored for two years to evaluate efficacy. This is a crucial step as India currently lacks a licensed dengue vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/54vZpRP
via IFTTT

Read More

Cipla eyes entry into India's weight management market amid rising demand and global competition

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening its central nervous system portfolio through strategic in-licensing deals and acquisitions, particularly in ADHD and Parkinson's disease. The company is also focusing on innovation-led solutions to combat antimicrobial resistance and aims to be a global, patient-centric healthcare leader.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CnbNVQU
via IFTTT

Read More

India's Ayush 'innovations' featured in WHO's brief on AI in traditional medicine

The WHO has lauded India's integration of Artificial Intelligence (AI) with traditional medicine systems like Ayush, acknowledging the country's efforts in a technical brief. This recognition follows India's proposal, leading to WHO's roadmap for AI in traditional medicine. India is using AI to advance Ayush systems through digital platforms, preserving traditional knowledge and promoting global healthcare integration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dphJrXa
via IFTTT

Read More

India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report

Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3kq04eV
via IFTTT

Read More

Wockhardt exits US generics biz to focus on drug discovery

Wockhardt is set to exit its loss-making US generics business to prioritize innovation, focusing on new antibiotic drug discovery and its biologics portfolio in insulin. The company has initiated voluntary liquidation for its US subsidiaries under Chapter 7 of the US Bankruptcy Code. This strategic shift allows Wockhardt to concentrate on high-impact areas and long-term value creation through scientific advancements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rc26b7Z
via IFTTT

Read More

Biosimilars to usher new growth, lead $1 trillion drug exports by 2030

India's pharmaceutical industry is targeting $1 trillion in drug exports by 2030, with biosimilars expected to be a major growth driver. The biosimilars market could exceed $60 billion by 2030, supported by Indian firms investing in biologics and advanced markets. Achieving this ambitious goal requires collaboration and a focus on innovation-driven categories.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pyYO9Eq
via IFTTT

Read More

Pharmexcil flags export disruption risk due to COPP mandate; seeks urgent review

Pharmaceutical Export Promotion Council of India wants Central Drugs Standard Control Organisation to rethink its online Certificate of Pharmaceutical Product submission rule. The council fears this could hurt India's drug exports, especially to Rest of World markets. They worry about delays in approvals. Pharmexcil has asked the Ministry of Health & Family Welfare and CDSCO to talk with exporters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WDQKnfL
via IFTTT

Read More

7 daily habits that silently damage your kidneys

Your kidneys quietly work to filter waste and balance your body’s fluids—but some everyday habits may be putting them at risk without you realising it. Here are 7 common behaviours that could be harming your kidney health over time.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NcHa5Ke
via IFTTT

Read More

Adani to create world-class, affordable, AI-first healthcare ecosystems

Gautam Adani unveiled plans for an AI-driven healthcare ecosystem in India, emphasizing affordability and scalability. He highlighted the need for a system-wide redesign, citing low back pain as a major disability. Adani announced Adani Healthcare Temples with Mayo Clinic's guidance, focusing on integrated care, technology, and skilled professionals to address healthcare gaps.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5sCUYaj
via IFTTT

Read More

PGIMER doctors perform India's first robot-assisted vasovasostomy

Doctors at PGIMER Chandigarh have achieved a groundbreaking feat by successfully performing India's first robot-assisted vasovasostomy. The urology team, led by Dr. Aditya Prakash Sharma, used the da Vinci Surgical System for enhanced precision in the male infertility surgery. This innovative approach offers new hope for couples seeking natural conception after vasectomy, marking a significant advancement in andrology and microsurgery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hQFxpN1
via IFTTT

Read More

Ichnos Glenmark, AbbVie ink USD 2-bn licensing deal for commercialisation of investigational asset

Glenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targeting cancer and autoimmune diseases. The deal, potentially worth up to USD 2 billion, grants AbbVie exclusive rights in major markets, while Glenmark will focus on emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MqsJ2Ro
via IFTTT

Read More

Lupin signs $50 million licensing deal with Zentiva to commercialise Certolizumab Pegol across global markets

Lupin Ltd has partnered with Zentiva Group to commercialize its biosimilar 'Certolizumab Pegol' across global markets. The agreement grants Zentiva commercialisation rights outside the US and Canada, primarily in Europe and CIS markets. Lupin will receive up to USD 50 million in milestone payments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c5ZStIC
via IFTTT

Read More

Granules India recalls 33,000 bottles of blood lowering medication in US

Granules India is recalling over 33,000 bottles of Metoprolol Succinate, a generic blood pressure medication, in the US due to manufacturing issues. The USFDA reported that the India-produced lot failed to meet dissolution specifications during stability studies. This Class II recall, initiated on June 24, indicates a potential for temporary or medically reversible health consequences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aPLj7Zr
via IFTTT

Read More

Pills & Profits: Can India's pharma sector handle Trump's planned 200% tariff dose?

India's pharma sector faces a potential challenge. The US considers high tariffs on drug imports. This could hurt Indian companies' profits and competitiveness. It might also raise medicine prices in America. India relies heavily on the US for pharma exports. Companies may need to explore new markets like Europe and Southeast Asia. The news impacted Indian stock markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3eP5Za6
via IFTTT

Read More

Pharma lobby flags 'cumbersome' export rule, seeks change

Pharma lobby groups are urging for changes to the centralized no-objection certification (NOC) for drug exports due to a significant export decline. The requirement for approvals from importing countries or Indian regulators has increased trade diversions. Industry experts are calling for a review of the provision, citing burdens on exporters and potential stifling of innovation, especially for MSMEs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8D1GLtI
via IFTTT

Read More

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

Nectar Lifesciences will sell its active pharmaceutical ingredients, formulation, and menthol business assets to Ceph Lifesciences for ₹1,290 crore. This strategic move involves a Business Transfer Agreement for the core API and formulation business at ₹1,270 crore and an Asset Purchase Agreement for the menthol business at ₹20 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ivWj9Rx
via IFTTT

Read More

Aster DM Healthcare sets sights on smaller cities to expand play, grab top spot

Aster DM Healthcare, after merging with Quality Care India, aims to become India's largest healthcare chain, surpassing Apollo Hospitals. Fueled by Blackstone's backing, Aster plans to increase bed capacity to 13,600 and expand into central India. The company anticipates improved margins through supply chain optimization and increased occupancy, targeting a 23-24% EBITDA margin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CVQ36Z0
via IFTTT

Read More

Delhi HC upholds order to restrain Rajasthan Aushdhalaya from making and selling medicines under Liv-333 name

The Delhi High Court has upheld a previous order restraining Rajasthan Aushdhalaya from selling medicines under the name Liv-333 or similar names, due to trademark infringement of Himalaya's Liv.52. The court found Rajasthan Aushdhalaya's adoption of 'Liv-333' as intentionally similar to capitalize on Himalaya's established reputation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Bo5pOHQ
via IFTTT

Read More

Indian Medical Association opposes decision to allow homeopaths to prescribe modern medicines post pharma course

The Indian Medical Association (IMA) has strongly criticised the Maharashtra Medical Council's (MMC) recent notification allowing homeopaths to prescribe modern medicines after a brief pharmacology course. IMA views this as misleading to patients and a dilution of modern medical practices. They highlight existing legal challenges and a stay order from the Bombay High Court, seeking expedited resolution.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q7HO9ik
via IFTTT

Read More

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Biocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These are biosimilars of Denosumab. Vevzuo addresses skeletal events in adults with advanced malignancies. Evfraxy treats osteoporosis and bone loss. This approval follows a similar authorization from the European Commission. It allows commercialization across the EU and EEA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CScevDN
via IFTTT

Read More

Union Health Minister JP Nadda, Delhi CM Rekha Gupta flag off Ayushman Bharat registration vans in New Delhi

Union Minister JP Nadda and Delhi CM Rekha Gupta launched Ayushman Bharat registration vans in New Delhi. Nadda criticized AAP for not utilizing allocated funds for the scheme. He praised Ayushman Arogya Mandir, contrasting it with AAP's Mohalla Clinics. Rekha Gupta and ministers inaugurated Ayushman Arogya Mandirs in Delhi. Ashish Sood distributed Ayushman Bharat cards to senior citizens in Janakpuri.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pz4MjSQ
via IFTTT

Read More

DRDO, AIIMS-Rishikesh ink MoU for clinical trials in field of biomedical devices

DRDO's Defence Institute of Physiology and Allied Sciences (DIPAS) and AIIMS, Rishikesh, have partnered to conduct clinical trials and advanced research. The collaboration aims to develop biomedical devices and supplements enhancing human performance in extreme environments. This joint effort will focus on creating products and technologies to mitigate the adverse effects of such environments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/R4XrpWa
via IFTTT

Read More

Niti to review concerns over pharma quality

Niti Aayog is addressing growing quality concerns in India's pharmaceutical industry by convening industry experts for discussions. The aim is to analyze the current state, understand challenges, and improve the quality of Indian pharmaceutical products to meet global standards. A meeting chaired by VK Paul will propose recommendations to ensure alignment with international regulations and patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GmwUWSu
via IFTTT

Read More

Lupin launches Ipratropium Bromide nasal spray in US

Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, bioequivalent to Boehringer Ingelheim's Atrovent, target rhinorrhea associated with allergies, nonallergic rhinitis, and the common cold. The annual sales for Ipratropium Bromide nasal solution (Atrovent) in the US were approximately USD 63 million, according to IQVIA MAT May 2025 data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PCLqjzw
via IFTTT

Read More

CBI searches premises of Pharmacy Council of India chief in corruption case

The CBI has booked Pharmacy Council of India President Montu M. Patel for alleged corruption and irregularities in pharmacy college approvals, conducting searches at his premises. Investigations revealed manipulated inspections, favouritism towards specific institutions, and electoral manipulation before Patel's presidential election. Approvals were granted despite negative reports, with evidence of bribery and infrastructural deficiencies in several colleges across multiple states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VEXimKg
via IFTTT

Read More

Hassan heart attack death cases: India’s top drugmakers rally behind Covid vaccines

Amid over 20 sudden heart attack deaths in Karnataka’s Hassan district, leading drugmakers have defended Covid vaccines on social media. Industry leaders including Dilip Shanghvi, Pankaj Patel, Satish Reddy, and Samir Mehta stressed there is no scientific link between the deaths and vaccination. The Karnataka health department has formed an expert panel to investigate. The Indian Vaccine Manufacturers Association and the Indian Pharmaceutical Alliance urged the public to trust India’s vaccine safety and rigorous approval process.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yrUVkHO
via IFTTT

Read More

COVID-19 vaccines well-documented, rigorously tested as per regulatory processes: IPA

The Indian Pharmaceutical Alliance (IPA) refuted claims linking COVID-19 vaccines to heart attack deaths, emphasizing their rigorous testing and crucial role in combating the pandemic. IPA Secretary General Sudarshan Jain highlighted the Indian pharmaceutical industry's knowledge-driven nature and its significant contribution to global vaccine production, accounting for 60% of the world's supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VxE9BGk
via IFTTT

Read More

Karnataka CM's remarks on covid vaccines 'factually incorrect,' says Biocon chief Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw refuted Karnataka CM Siddaramaiah's claim. Siddaramaiah linked covid-19 vaccines to heart attack deaths in Hassan. Shaw stated the vaccines followed rigorous safety protocols. She said the vaccines saved lives. The Union Health Ministry dismissed Siddaramaiah's statement. Studies show no link between vaccines and sudden deaths. The ministry cited various factors for cardiac deaths.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/orBn0vj
via IFTTT

Read More

Delhi HC seeks regulator's reply after PIL questions Ozempic, Mounjaro nod

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like Ozempic and Mounjaro. A public interest litigation raised questions about safety data and clinical trials. The court wants the regulator to consult experts and manufacturers. Ozempic is available in the grey market, though not officially sold in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fn2M7o
via IFTTT

Read More

Auriga Research, SFRI ink pact to advance clinical research, AI-driven support for healthcare industry

Auriga Research partners with San Francisco Research Institute. The collaboration focuses on global clinical research. It will promote AI-integrated healthcare solutions. The partnership aims to expand access to wellness products in India, the US, and Africa. SFRI will support regulatory strategy and commercial partnerships. Both organizations will expand their Research Training Program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xCXdjrv
via IFTTT

Read More

Cipla in talks to add new customers for its China factory, executive says

Indian pharmaceutical giant Cipla is exploring at least two new overseas markets for products made at its Chinese manufacturing plant, as it grapples with limited production capacity in India. The company began producing inhalation respule products at its Jiangsu facility in 2024 to supply the U.S., and is now in talks with other countries to expand exports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eEWsRNJ
via IFTTT

Read More

Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and Wegovy

Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canada, where patents expire next year. Managing Director Siddharth Mittal sees Canada as a prime opportunity, aiming for potential approval in 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SAtE7h3
via IFTTT

Read More

Apollo Hospitals to spin off digi health, pharmacy business

Apollo Hospitals is demerging its omnichannel pharma and digital health businesses into a new entity, aiming for a separate listing. This move creates India's largest omnichannel pharmacy platform with a revenue target of ₹25,000 crore by FY27. The promoter family will hold approximately 36.5% in the new company, with Shobana Kamineni as the executive chairperson.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yzOGd41
via IFTTT

Read More

Wockhardt activates Zaynich push, eyes global licensing deals

Wockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions in the US and India. The company is exploring out-licensing deals while preparing for potential solo commercialization in key markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AQmcYDl
via IFTTT

Read More

After a robust march, pharma exports slow

India's pharmaceutical exports experienced a modest 1.5% growth in April and May, following a significant 31.2% surge in March driven by year-end targets and anticipation of US tariffs. Despite pricing pressures and regulatory scrutiny, shipments to the US rose 20.4% to $10.5 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U6crY4N
via IFTTT

Read More

Torrent Pharma set to finalise JB Chemicals buyout in 15-18 months

Torrent Pharmaceuticals is set to acquire JB Chemicals & Pharmaceuticals, with the deal expected to finalize in 15-18 months, pending regulatory approvals. The acquisition, primarily debt-funded, aims to enhance Torrent's presence in the Indian market, particularly in high-growth segments like cardiac and gastroenterology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BtDPmXi
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic cancer treatment injection

Alembic Pharmaceuticals has received final USFDA approval. This approval is for its generic Doxorubicin Hydrochloride Liposome injection. The injection comes in strengths of 20 mg/10 mL and 50 mg/25 mL. It is used to treat ovarian cancer, AIDS-Related Kaposi's sarcoma, and multiple myeloma. The market size for this injection is estimated at USD 29 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CWsE2vP
via IFTTT

Read More

Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation

Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dNEK69B
via IFTTT

Read More

Clear & Legible: Labelling on drug packets to get a booster

Concerns arose regarding medicine labels. Consumers struggled to read expiry dates. The shiny surface of strips posed readability issues. The Drugs Consultative Committee addressed the matter. A sub-committee will examine packaging in detail. They will assess regulations for packaging suppliers. The government considers voice-assisted QR codes. Braille cards on strips are also under consideration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lFbvXEj
via IFTTT

Read More

Torrent Pharma to buy controlling stake in JB Chemicals from KKR for Rs 25,689 crore

Torrent Pharmaceuticals is set to acquire a 46.39% controlling stake in JB Chemicals and Pharmaceuticals from KKR for ₹11,917 crore, valuing JB Pharma at ₹25,689 crore. Following the acquisition, Torrent plans a merger, pending regulatory approvals, and will launch an open offer to public shareholders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vPMNtoa
via IFTTT

Read More

Torrent, JB Chemicals finalising steps for two-stage merger, combine may find place in pharma big 5

Torrent Pharmaceuticals and JB Chemicals & Pharmaceuticals are finalizing merger terms in a two-stage deal. Torrent will first acquire KKR's 47.84% stake in JB Chemicals for approximately ₹13,433 crore, financed by global banks, potentially triggering an open offer. The subsequent merger aims to create synergies, positioning Torrent among India's top five pharma players with a combined value of ₹1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2PNfkOi
via IFTTT

Read More

From pediatrics to cardiac care: Leading Chennai’s healthcare landscape with compassion and cutting-edge innovations

Dr. Mehta’s Hospitals in Chennai has a 92-year legacy. It began as a small nursing home. Now it is a multi-speciality institution. The hospital focuses on pediatric and cardiac care. It also provides comprehensive women’s health services. The hospital has NABH and NABL accreditations. It trains future medical professionals. Dr. Mehta’s aims to provide clinically strong and tech-enabled healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9SlAZRG
via IFTTT

Read More

Eli Lilly to roll out diabetes medicine in prefilled pen

Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The KwikPen offers a convenient, once-weekly administration. It contains four fixed doses. This launch intensifies competition with Novo Nordisk's Wegovy. Mounjaro's dual mechanism may offer superior efficacy. The availability of all six dosage options will support personalized treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yKveCG0
via IFTTT

Read More

Lupin launches generic chronic constipation treatment drug in US

Mumbai-based Lupin Ltd has introduced its generic Prucalopride tablets in the United States. This launch follows approval from the US health regulatory body. The tablets, available in 1 mg and 2 mg strengths, treat chronic idiopathic constipation in adults. These tablets are bioequivalent to Takeda Pharmaceuticals' Motegrity tablets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wL2lOsr
via IFTTT

Read More

Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy

Eli Lilly announced that India’s drug regulator has approved its Mounjaro KwikPen, a pre-filled injector pen for weight loss and diabetes treatment. Previously available only in vials, Mounjaro will now be offered in six dose strengths, enhancing convenience and competitiveness against Novo Nordisk’s newly launched Wegovy, which also features a user-friendly pen format.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MSnrD85
via IFTTT

Read More

Pharma companies may lose licence if drugs fail tests

The health ministry is considering strict actions, including immediate license suspensions, for drugmakers producing substandard drugs. This proposal follows concerns about quality control and aims to safeguard public health. Pharma lobby groups have raised objections, citing technical issues and questioning the standards of government testing laboratories, while advocating for a stronger recall mechanism.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GeNpgHz
via IFTTT

Read More

Lupin gets USFDA nod for generic chronic constipation treatment drug

Lupin Limited has received the United States Food and Drug Administration approval for its generic version of Prucalopride tablets. These tablets are used for treating chronic idiopathic constipation. The approved strengths are 1 mg and 2 mg. This generic medicine is bioequivalent to Takeda Pharmaceuticals' Motegrity tablets. Lupin will manufacture the product at its Goa facility in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UYvFxtq
via IFTTT

Read More